Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Naturally Splendid Enterprise, Ltd. (NSP.V) (NSPDF) Presentation
https://www.youtube.com/watch?v=QgGlRhORvew" rel="nofollow" target="_blank" >https://www.youtube.com/watch?v=QgGlRhORvew
New treatment for diabetic macular edema
Iluvien on TV
wnyt.com/article/stories/s3719917.shtml
Jespal Deol, Chief Executive Officer of Graphene NanoChem, commented:
"The combined strength of our unique product solutions and the strategy to deploy our products through a partnership model with a respected industry player is bearing fruit with the deployment of our third oilfield product through Scomi Oiltools. We are working hard with Scomi Oiltools in executing the process that would allow the substitution of products in existing drilling programmes as well as directly introducing our products in new tenders participated by Scomi Oiltools as part of our immediate and long term growth plan for this market and are very much encouraged with the progress achieved."
www.investegate.co.uk/graphene-nanochem--grph-/rns/deployment-of-oilfield-recovery-additive/201503041404145480G/
Graphene NanoChem's PlatsurF deployed
4 March 2015 | 14:15pm
StockMarketWire.com - Graphene NanoChem has announced the commercial deployment of its oilfield recovery additive (PlatsurF) as the group continues to execute its go-to-market channel via its joint venture partner, Scomi Oiltools.
Highlights:
· Order from Scomi Oiltools for an international oil company end customer serviced by Scomi Oiltools for an approximate 50-well drilling programme in Thailand · Initial deployment of 40 drums of recovery additive for 2 wells in Thailand as part of the initial phase of field introduction under a change order process with Scomi Oiltools for product substitution
· The revenue from the initial purchase order for 40 drums is estimated to be US$162,000
Oilfield recovery additive offers a unique nanoemulsion solution to remove blockages caused by drilling residues or from production waste and is a solution to shortfalls in production caused by formation damage. The smartfluids solution vastly improves production rates in previously damaged wells with reduced waste generation. The Scomi Oiltools, order book currently stands at RM5.3bn and together with its existing contract base with national and international oil companies provides a significant market opportunity for the joint venture in terms of product substitution. The partnership with Scomi has enabled the Group to significantly minimise its marketing and adoption risk and accelerate the commercial deployment of its products via Scomi Oiltools' existing customer base.
www.stockmarketwire.com/article/4989045/Graphene-NanoChems-PlatsurF-deployed.html
Naturally Splendid Enterprises appoints Racz to board
2015-03-02 10:03 ET - News Release
Mr. Craig Goodwin reports
FORMER PFIZER EXECUTIVE DAVID RACZ APPOINTED DIRECTOR, NATURALLY SPLENDID LTD AND PRESIDENT OF NATURALLY SPLENDID USA
www.stockwatch.com/News/Item.aspx?bid=Z-C:NSP-2255512
BioMark Announces Grant Funded Partnership With TMIC
www.fscwire.com/newsrelease/biomark-announces-grant-funded-partnership-tmic
BioMark Brings New Life to Cancer Detection Technology
www.biomarkdiagnostics.com/biomark-brings-new-life-to-cancer-detection-technology/
BioMark Announces Private Placement
www.fscwire.com/newsrelease/biomark-announces-private-placement
Naturally Splendid Launches 100% Owned Pet Care Line
February 26, 2015 / TheNewswire / Vancouver, BC – Naturally Splendid Enterprises (the “Company”) (NSP – TSX Venture) (NSPDF – OTCQB) (50N – Frankfurt) is pleased to announce the launch of a 100% owned hemp-based pet care line trademarked Pawsitive FX™ and the launch of the new Corporate company Website at www.naturallysplendid.com. The new website will go live at 6:30am PST on Feb. 26, 2015.
The initial Pawsitive Fx™ product line consists of three formulations for topical applications as well as 3 formulated shampoo products.
Company Director and VP of Operations Bryan Carson reports, “The pet industry in Canada, the United States and many other countries is booming. Americans, for example, own more pets than ever before and according to the American Pet Product Association (APPA), spent approximately $47.7 billion on pet products and services in 2010. Growth in the sector can be attributed to increasing pet ownership and increased spending per pet. Pet pampering is becoming the norm, as pet owner spending has moved far beyond simple food and grooming expenses to include innovative and specialized premium products. This trend has driven Naturally Splendid to develop a line of natural pet care products, custom formulated and manufactured in Vancouver BC, based on the ever amazing benefits derived from hemp-oil based formulations”.
Company CEO Craig Goodwin adds, “As reported in a Jan. 28, 2015 news release, Naturally Splendid Enterprises announced the signing of a Service Agreement with Alberta Agriculture and Rural Development's Food Science and Technology Center (FSTC) in Brooks, Alberta. The FSTC is one unit of the Food and Bio Processing Division of Alberta Agriculture and Rural Development and has scientists that specialize in pet food products. The purpose of that project is directed to pet food products. We wanted to offer a range of pet products in addition to pet food and have thus developed a topical pet care products line”.
Consumer demand for pet food, health and wellness products, grooming and pet related accessories is growing at a rate of 4% annually according to Packaged Facts (1). The overall market in Canada for pet related items reached $6.6 billion in 2012 and is expected to grow to $8.3 billion by 2018. "Consumers spend an average of nearly $1000/year on their pets. Pet-related spending will continue to increase rapidly over the coming years, due in large part to the aging pet population, and owners seeking higher quality food for their pets (2). The new generation of pet owners is both willing and able to pay top dollar for premium products. They are concerned about their pets' health and welfare. Recent and emerging trends in the market include: a focus on nutrition, an interest in low calorie or light products; increased availability of nutraceutical products with supported health claims; and, gourmet and specialty pet foods and snacks.
The Company plans to generate sales of Pawsitive FX™ products by utilizing its existing distribution network, develop additional pet specific distribution networks and generate on-line sales.
- See more at: thenewswire.ca/archives?tnwcatalyst2=release_id=15714#sthash.gPbhPD1K.dpuf
Graphene NanoChem JV gets tax exemption
24 February 2015 | 09:26am
StockMarketWire.com - Scomi-Platinum Sdn Bhd - Graphene NanoChem's joint venture with Scomi Oiltools - has been granted a pioneer status for strategic project approval by Malaysia's Ministry of International Trade Industry for the planned 45,000 MT per annum nano-enhanced oil field chemicals facility in Port Klang.
Tthe Scomi-Platinum JV has been granted a full 10-year 100% tax-exempt status for its statutory income under which it is fully exempted from paying corporation tax on taxable income. Malaysia currently imposes a fixed rate of 25% corporate tax on chargeable income.
Graphene NanoChem chief executive Jespal Deol said: "We are highly encouraged by the strong support we continue to receive from the Government of Malaysia in advancing our technology platform and the growth plan of our business and this latest progress provides a significant financial benefit to the Group moving forward."
- See more at: www.stockmarketwire.com/article/4982529/Graphene-NanoChem-JV-gets-tax-exemption.html#sthash.dOAVEsCX.dpuf
Resumption of trading
Naturally Splendid's common shares will resume trading under the symbol NSP on Feb. 26, 2015.
Naturally Splendid USA completes acquisition of licence
2015-02-25 09:36 ET - News Release
Mr. J. Craig Goodwin reports
NATURALLY SPLENDID USA CLOSES TRANSACTION TO LICENSE HEMP AND CANNABINOID EXTRACTION AND FORMULATION AND NATURALLY SPLENDID CLOSES $1,847,132 FINANCING
Naturally Splendid USA Ltd., Naturally Splendid Enterprises Ltd.'s wholly owned subsidiary, has closed the novation agreement with Full Spectrum Laboratories Ltd. (FSL), Boreal Technologies Inc. and Naturally Splendid, whereby Boreal has assigned, and Naturally Splendid USA has assumed, all rights, title and interest in and to a restated and amended licence agreement between FSL and Boreal.
www.stockwatch.com/News/Item.aspx?bid=Z-C:NSP-2253747
Naturally gains conditional TSX-V OK for licensing deal
2015-02-10 16:08 ET - News Release
Mr. J. Craig Goodwin reports
NATURALLY SPLENDID CORPORATE UPDATE
Naturally Splendid Enterprises Ltd. is providing an update in connection with the TSX Venture Exchange review of Naturally Splendid's transaction with Full Spectrum Laboratories Ltd. (FSL) pursuant to the terms of a novation agreement among FSL, Boreal Technologies Inc., Naturally Splendid USA Ltd., a wholly owned subsidiary of Naturally Splendid, and Naturally Splendid. As set out in the news release dated Nov. 20, 2014, Naturally Splendid has agreed to license from FSL certain technologies relating to omega extraction and formulations, and cannabinoid (CBD) extraction and formulations.
Naturally Splendid is pleased to state that the TSX-V has provided conditional acceptance of the transaction, subject to receipt of satisfactory final documentation, closing of the previously announced private placement financing and satisfying certain conditions of the TSX-V. In particular, Naturally Splendid has agreed to not produce, sell or market any products utilizing the CBD technology until it has obtained a satisfactory opinion on the legality of these products and the acceptance of the TSX-V.
Naturally Splendid will focus its resources on selling those products developed utilizing the omega technology, such as HempOmega. Currently, Naturally Splendid is actively developing proprietary formulations incorporating HempOmega, as well as working closely with Nature's Health Products Canada Corp. (NHPCC), a member of the POS Group of Companies based in Saskatoon, Sask., to capitalize on immediate opportunities to present and sell bulk volumes of HempOmega to selected clients.
On closing of the private placement financing and the novation agreement, Naturally Splendid anticipates that the TSX-V will remove the trading halt of its common shares.
About Full Spectrum Laboratories
Full Spectrum Laboratories, incorporated in Ireland, is a bioresearch and product development company with operating subsidiaries in Canada and the United States. The company has principally focused on the plant cannabis sativa, and has developed numerous technologies and made several discoveries, resulting in two granted patents and over 11 patent applications in just under five years. FSL currently concentrates on formulation and extraction technologies; analytical cannabis testing in Canada; advanced cannabis plant breeding, specializing in CBD expression; and cannabinoid biosynthesis.
We seek Safe Harbor.
Trading halt
Naturally Splendid halted at open
2014-11-18 07:54 ET - Halt Trading
Naturally Splendid Enterprises Ltd. has been halted at the open on Nov. 18, 2014, at the request of the company, pending an announcement.
FSL is excited to partner with Naturally Splendid and grow with them in the future, which is [why] we have negotiated a certain portion of our licence fees to be provided in the common shares of Naturally Splendid."
upgrade to buy
Results for the first six months ended June that were relaeased on September 30 disappointed investors as the company warned on contract delays. The profit warning sent shares crashing by 32.4pc – a decline of 18.375p to 38.375p – in particular it was sluggish signing on the graphene-enhanced biodegradable oilfield drilling fluid that was the problem.
The orders may have been delayed but they haven’t disappeared altogether.
The company said yesterday that it had agreed a second commercial order of its graphene enhanced drilling fluid called PlatDrill. The order signed with Scomi Oiltools and valued at $4.8m is three times the size of the previous contract.
The announcement came alongside an agreement, sealed with Shell Malaysia, to provide a palm oil-based biofuel additive for diesel products. The contract is for one year starting in November to provide 5m litres per month of PlatAmber. However, the biofuel additives are not graphene enhanced and are lower profit margin.
Jespal Deol, chief executive, is confident that the contract wins now underpin revenues for 2015. Sales are expected to rise about 50pc next year from a target of around £50m this year and a larger proportion of those sales, thought to be in the region of 30pc, will come from higher profit margin PlatDrill products.
Graphene Nanochem is a high-risk investment but if those sales come through as expected, and with new graphene products in the pipeline, the shares are definitely one to watch and we upgrade to buy.
www.telegraph.co.uk/finance/markets/questor/11144349/Questor-share-tip-Graphene-Nanochem-wins-contracts.html
EDAP TMS today announced the first successful treatments performed at Germany's Mannheim University Hospital ("UMM"), using the Company's Focal One® HIFU device.
Marc Oczachowski, EDAP's Chief Executive Officer, added, "We are very pleased to add one of the largest German Prostate Cancer Centers, Mannheim University Hospital, to our growing number of Focal One adopters. This trend confirms the positioning of our Focal One HIFU system as a viable complement to current prostate cancer treatments at leading Institutions."
EDAP TMS recently presented its innovative technologies at the 66th Congress of the German Society of Urology held October 1 – 4, 2014, in Dusseldorf, Germany. The Company's presentation included live Focal One demonstrations, which were well-attended by urologists. Feedback from the demonstrations confirmed significant physician interest in adopting this HIFU tool to address the needs of prostate cancer patients.
www.marketwatch.com/story/edap-announces-sale-of-focal-oner-hifu-device-to-mannheim-university-hospital-germany-2014-10-07?siteid=nbsh
NEWS: Naturally Splendid to license cannabis tech from FSL
2014-10-07 08:26 ET - News Release
Mr. Craig Goodwin reports
NATURALLY SPLENDID SECURES GLOBAL LICENSING AGREEMENT FOR WORLD'S FIRST PATENTED WATER SOLUBLE CANNABINOID TECHNOLOGY
www.stockwatch.com/News/Item.aspx?bid=Z-C:NSP-2216998
FDA Approval of ILUVIEN® for DME: Company Reaches Inflection Point
Posted on Monday, October 6th, 2014 at 8:00 am
- See more at: www.thechairmansblog.com/psivida/paul-ashton/fda-approval-iluvien-dme-company-reaches-inflection-point/#sthash.Ct4uT72o.dpuf
Next: Third Term Contract Renewal With Shell
Graphene NanoChem PLC
("Graphene NanoChem" or the "Group")
Third Term Contract Renewal With Shell
Graphene NanoChem (AIM: GRPH), the performance nanochemicals and advanced materials company, is pleased to announce that Platinum NanoChem Sdn Bhd, its wholly-owned subsidiary, has been awarded a contract renewal by Shell Malaysia for the supply of up to 5 million litres per month of PlatAmber, the Group's biofuel product derived from palm waste for the Malaysian market.
Details: www.investegate.co.uk/graphene-nanochem--grph-/rns/third-term-contract-renewal-with-shell/201410060700074668T/
Next good news:
03 October 2014
For Immediate Release 3 October 2014
Graphene NanoChem PLC
("Graphene NanoChem" or the "Group")
Malaysia Green Technology Award
Graphene NanoChem (AIM: GRPH), the performance nanochemicals and advanced materials company, is pleased to announce that the Scomi-Platinum joint venture company ("Scomi-Platinum JVCo") has been awarded up to GBP9.4 million in Government-backed debt guarantee for its Plat Drill Series and performance chemicals Facility ("the Facility").
The guarantees from the Malaysian government ("Government") include:
-- Providing Government guarantees for up to 60% of debt financing package, subject to a maximum amount of GBP9.4 million, for the construction of the Facility ("Project Debt Financing");
-- Subsidising 2% of the total interest charged by the financial institutions providing the Project Debt Financing.
The Facility in Port Klang, Malaysia provides high quality earnings, with high visibility, over a long period of time with guaranteed offtake of 135,000 tonnes of the PlatDrill Series over a period of 5 years from Scomi Oiltools.
Jespal Deol, Chief Executive Officer of Graphene NanoChem, commented: "We are delighted by the award from the Malaysian Government, further validating our innovative technology platform".
de.advfn.com/p.php?pid=nmona&article=63908867
second commercial order
1 October 2014
Graphene NanoChem PLC
("Graphene NanoChem" or the "Group")
PlatQuartZ Commercial Deployment
Graphene NanoChem (AIM: GRPH), the performance chemicals and advanced materials company, is pleased to announce the receipt of the second commercial order of the PlatQuartZ Series, its second high value graphene-enhanced products line for the oilfield chemicals market, valued at US$5.6 million.
Highlights
· Second commercial order of 2,640 drums of the PlatQuartZ Series, representing 6 fold increase over the first commercial order of 380 drums announced by the Group yesterday;
· Order from Scomi Oiltools Sdn Bhd ("Scomi Oiltools") for dispersion into water and oil based drilling systems and deployment to a National Oil Company;
· The revenue from the commercial order is US$5.6 million.
The PlatQuartZ Series offers high performance non-toxic lubricant additive solution for oilfield drilling, designed to enhance drilling rates by improving drilling efficiency and increasing wellbore stability with market-leading enhancement in torque and drag reduction.
Jespal Deol, Chief Executive Officer of Graphene NanoChem, commented: "We are delighted to announce the increase in sales of our PlatQuartZ Series that will boost revenues for the fourth quarter, further validating the commercial rollout of our products into the oilfield chemicals marketplace through our partnership with Scomi. We anticipate further orders for the PlatDrill Series in the near term.
www.investegate.co.uk/graphene-nanochem--grph-/rns/platquartz-commercial-deployment/201410010841551246T/
Thanks for the quick reply.
Financial Highlights
· Revenue up 103% to £20.4m (H1 2013: £10.1m)
· Gross profit/(loss) £0.1m (H1 2013 : (£0.8m))
· Loss before tax of £3.5m (H1 2013: £5.4 m)
· Cash and cash equivalents of £2.8m (FY 2013 : £7.4m)
· £23.8m of cash and working capital facility, in aggregate (FY 2013: £20.4m)
· While the Group looks ahead to an exciting 2015, there have been a series of delays in the deployment of the Plat Drill Series, due to both regulatory and testing constraints. Management now believes that these delays will result in revenue previously forecast to fall into FY2014 being partially recognised in FY2104 and FY2015, as a result management now anticipates making a loss for the year to 31 December 2014. The Company still remains optimistic for 2015 and beyond, however the latest delays mean that results to 31 December 2014 are now likely to be significantly below current market expectations.
www.investegate.co.uk/graphene-nanochem--grph-/rns/interim-results/201409300700439592S/
When will PSIVIDA get the 25 million of Alimera?
Is it a one-off payment or a payment in several installments?
LONDON (Alliance News) - Graphene NanoChem PLC Thursday said it has signed a licensing agreement and an offtake contract for the entire production of PlatDrill, a drilling fluid, under its Scomi-Platinum joint venture in Malaysia.
The joint venture between Graphene NanoChem's wholly-owned subsidiary, Platinum NanoChem Sdn Bhd, and a subsidiary of Scomi Energy services Bhd, Scomi Oiltools Sdn Bhd, was announced in April. Both companies have a 50% interest.
The joint venture is for the construction and operation of an integrated 45,000 tonnes per annum chemicals production facility, including a 30,000 tonnes per annum PlatDrill production plant and a 30 tonne per annum graphene nanomaterials facility in Port Klang, Malaysia, dedicated to supplying the oilfield chemicals market.
PlatDrill is a graphene-enhanced biodegradable drilling fluid, which Graphene NanoChem said offers significant operational benefits over traditional substances.
As part of the agreement, an offtake contract locks in the guaranteed sale, over a five-year period, of 135,000 tonnes of PlatDrill once the Port Klang plant has been commissioned, with an option for Scomi Oiltools to renew it for a further 5 years, it added.
Scomi is planning for the start up of the Port Klang Plant in the second-quarter of 2016 and is currently in discussion with several financial institutions to finalise the debt financing package for the joint venture, said Graphene NanoChem.
Chief Executive of Graphene NanoChem, Jespal Deol said the "partnership provides us with a ready-made market through Scomi's strong presence in the oil and gas service sector."
"The collaboration with Graphene NanoChem enables Scomi Oiltools to be a provider of game changing, cutting-edge and environmentally green drilling solutions which enable time and cost savings for our customers," added Wan Salaidin, president of market units at Scomi.
www.lse.co.uk/AllNews.asp?code=hvh1a3bk
14 August 2014 | 09:07am Graphene NanoChem, the performance nanochemicals and advanced materials company, has filed a Malaysian patent application in relation to a unique method of making graphene nanocomposites by multiphase fluid dynamic dispersion. Graphene NanoChem's multiphase fluid dispersion device, PlatSperse, provides a significant enhancement to the Group's platform in graphene dispersion and enables Graphene NanoChem to explore a more diverse range of applications with a view to commercialising graphene enhanced products. www.stockmarketwire.com/article/4868480/Graphene-NanoChem-files-new-patent.html#sthash.zPk1V6w4.dpuf
Graphene NanoChem files two new patents
7 August 2014 | 08:04am
StockMarketWire.com - Graphene NanoChem (AIM: GRPH), the performance nanochemicals and advanced materials company, has announced the expansion of its nanomaterials products portfolio with the filing of two new patents for graphene nanomaterials production.
These are the "Method of Production of Graphite Nanofiber" and the "Method of Making Graphene by Multiphase Fluid Dynamic Exfoliation".
The patent applications filed relate to two different types of graphene nanomaterials developed for specific sets of applications areas.
The Group will be seeking to extend the patent protection for its latest inventions in selected jurisdictions worldwide.
Jespal Deol, chief executive officer of Graphene NanoChem, commented: "There are a wide range of graphene nanomaterials - each having differing properties and strengths and addressing different markets depending on the targeted functional use. As part of our long-term strategy, we will continuously invest in building our nanomaterial products portfolio that would allow us to explore commercial applications of graphene nanomaterials in strategic growth areas."
At 8:04am: [LON:GRPH] Graphene NanoChem PLC share price was 0p at 50p
- See more at: http://www.stockmarketwire.com/article/4864489/Graphene-NanoChem-files-two-new-patents.html#sthash.mj38tegE.dpuf
Graphene NanoChem files two new patents
7 August 2014 | 08:04am
StockMarketWire.com - Graphene NanoChem (AIM: GRPH), the performance nanochemicals and advanced materials company, has announced the expansion of its nanomaterials products portfolio with the filing of two new patents for graphene nanomaterials production.
These are the "Method of Production of Graphite Nanofiber" and the "Method of Making Graphene by Multiphase Fluid Dynamic Exfoliation".
The patent applications filed relate to two different types of graphene nanomaterials developed for specific sets of applications areas.
The Group will be seeking to extend the patent protection for its latest inventions in selected jurisdictions worldwide.
Jespal Deol, chief executive officer of Graphene NanoChem, commented: "There are a wide range of graphene nanomaterials - each having differing properties and strengths and addressing different markets depending on the targeted functional use. As part of our long-term strategy, we will continuously invest in building our nanomaterial products portfolio that would allow us to explore commercial applications of graphene nanomaterials in strategic growth areas."
At 8:04am: [LON:GRPH] Graphene NanoChem PLC share price was 0p at 50p
- See more at: http://www.stockmarketwire.com/article/4864489/Graphene-NanoChem-files-two-new-patents.html#sthash.mj38tegE.dpuf
FINANCIAL HIGHLIGHTS
· Revenue for the three months ended 30 June 2014 of £7.6 million ($13.0 million) compared to £7.3 million for the three months ended 30 June 2013
· Loss for the three months ended 30 June 2014 of £6.9 million ($11.9 million) compared to a loss of £2.0 million for the three months ended 30 June 2013. The increased loss primarily reflects the planned increase in GW funded R&D in order to fund the development of Epidiolex and other pipeline candidates
· Cash and cash equivalents at 30 June 2014 of £168.3 million ($287.8 million) compared to £38.1 million as at 30 September 2013
"During the third quarter GW announced important initial data on Epidiolex which provides promising signals of efficacy in children with treatment-resistant epilepsy, including patients with Dravet syndrome. Our preparations for Phase 3 clinical trials in both Dravet and Lennox-Gastaut syndromes are advancing rapidly and we look forward to the start of the first pivotal placebo-controlled trial in the second half of this year. The funds raised this quarter in the follow-on offering will not only allow GW to complete these development programs but also to commence pre-launch activities in the United States and build-up of inventory in readiness for future launch," stated Justin Gover, GW's Chief Executive Officer. "In parallel with GW's Epidiolex program, we are also progressing towards the conclusion of our U.S. Phase 3 cancer pain trials for Sativex and look forward to reporting initial top-line data from the first trial around the end of 2014. Finally, we continue to make strong progress across our cannabinoid pipeline, which continues to yield interesting new product candidates in a wide variety of therapeutic areas."
www.investegate.co.uk/gw-pharmaceuticals--gwp-/rns/third-quarter-financial-results/201408060700073523O/
Key points from Mr. Oczachowski included:
Ablatherm-HIFU has a proven safety record through its approval and use in markets including Europe, Canada, Russia, Brazil, Mexico and South Korea;
Ablatherm has treated more than 40,000 prostate cancer patients worldwide since its initial CE Mark approval in 2000;
Recently the French Ministry of Health approved HIFU reimbursement for primary care patients at the same level as surgery;
The Panel apparently agreed that the current approval path for new prostate cancer treatments is prohibitive and the likelihood that existing therapies, if evaluated on today's requirements, would be unlikely to qualify for a positive vote;
Mr. Oczachowski added, "We believe there is strong clinical evidence supporting the safety of our Ablatherm Integrated Imaging HIFU device. Indeed after 15 years of routine use, we see a growing adoption of the technology with approximately 4,000 treatments performed annually. To date, there have been no restrictions placed on the use of Ablatherm-HIFU from any of the numerous regulatory authorities under which it has been approved. If Ablatherm HIFU was dangerous or unsafe, it would not have survived more than five years in any market and would not be used by any urologist or would be forbidden by regulatory authorities around the world, this is not the case. We also believe that if it was not effective nor answering some patient needs, urologists around the world would have stopped using it."
www.benzinga.com/news/14/08/4756256/edap-ceo-comments-on-frustration-with-fda-panel
Mr. Oczachowski concluded, "Based on the panel comments, we could interpret that applying today's standards to all available treatment options would result in no therapeutic options for low-risk prostate cancer patients in the U.S. Finally, we strongly believe that there are probably more risks in excluding a technology that has 15 year proven experience from the American patient choice than having it available in a controlled and monitored environment in the country, as it could result in an increasing HIFU medical tourism with the known risks associated."
www.sharedeals.de/2014/07/31/edap-tms-rauscht-in-die-tiefe-fda-gnadenlos/
google translation:
The performance of the past few days had already indicated: The U.S. Food and Drug Administration is the "Ablatherm" EDAP TMS of (WKN: 908 548) does not allow all probability this year. The device for the treatment of prostate cancer by ultrasound was the expert committee by merciless and received in terms of efficiency due to missing or inadequate data 9 of 9 negative votes. Only when it comes to safety, three of the FDA experts opted for a positive judgment. The final decision of the authority is not bound by the recommendation of the Committee, but it is expected to follow according to experience. In Europe and other parts of the world Ablatherm's been eingier time in use and made for EDAP, along with other products already for a positive Q1 result. Life-threatening delayed the U.S. launch for the company is by no means, but he probably prevented a medium-term revenue and profit explosion. In the wake of the euphoria EDAP share climbed from April to July by over 100% in the air, but lost alone after yesterday's announcement of the expert vote after trading hours at times around 50% in value.
ILUVIEN Receives Marketing Authorization in Norway and Approval for Reimbursement in Portugal
28.07.2014 | 22:20
Business Wire·Mehr Nachrichten von Business Wire
pSivida Announces ILUVIEN Receives Marketing Authorization in Norway and Approval for Reimbursement in Portugal
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that ILUVIEN® has been has granted marketing authorization in Norway for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies and has been approved for reimbursement in Portugal for the same indication.
The Norway marketing authorization is the first following the successful completion last month of the Mutual Recognition Procedure for Norway and nine other EU countries. Marketing authorization is pending in the remaining nine countries (the Czech Republic, Denmark, Finland, Ireland, Luxembourg, the Netherlands, Belgium, Poland and Sweden).
ILUVIEN has been approved for reimbursement in Portugal by INFARMED, the marketing authorization body of the Portuguese Ministry of Health. Alimera has reported it plans to move forward with commercialization in Portugal in late 2014.
ILUVIEN is commercially available in the U.K. and Germany and has marketing authorization in Austria, Portugal, France, Spain and Italy. ILUVIEN is currently under review by the U.S. Food and Drug Administration with a Prescription Drug User Fee Act (PDUFA) goal date of September 26, 2014.
"We are very pleased at the steady progress ILUVIEN is making in Europe and look forward to the PDUFA date," said Dr. Paul Ashton, President and CEO of pSivida. "Should ILUVIEN be approved by the FDA, we are entitled to a $25 million milestone payment from Alimera in addition to net profit payments on Alimera's sales of ILUVIEN."
2. What documents are required for a stock split?
The company needs to complete the Issuer Company-Related Action Notification Form and submit to FINRA no later than 10 calendar days prior to the record date of the corporate action. Submissions can be set via email or fax to (202) 689-3533. Failure by an OTC Equity issuer to provide the requisite notice may constitute fraud under Section 10 of the Securities Exchange Act of 1934.
www.finra.org/Industry/Compliance/MarketTransparency/UPC/FAQ/P117315#2-2
deal guy said:
"FINRA can't tell him to split or not. That is a responsibility of the SEC.
If he doesn't know the difference between the SEC and FINRA who can beleive one other word out of his mouth."
NOTIFICATION OF MAJOR INTEREST IN SHARES
Tuesday 08 July, 2014
www.investegate.co.uk/gw-pharmaceuticals--gwp-/rns/holding-s--in-company/201407081018267127L/
One more:
Graphene NanoChem jumps 17% on milestone order
Company signs deal with Scomi Oiltools for oilfield chemicals
It takes something to outpace a newly revealed takeover target, but Graphene NanoChem has done the trick.
Mothercare has jumped nearly 12% after the revelation of a US bid approach, but the advanced materials group is up 8.5p or almost 17% at 59p after it unveiled the first order for its graphene-enhanced oilfield chemicals.
The revenue from the initial order from Scomi Oiltools is expected to be around £1m, the company said. The deal is said to be the first bulk deployment of graphene - which conducts electricity better than copper and is 200 times stronger than steel and six times lighter - on a commercial basis, thus marking a milestone for the industry. It follows two years of testing by Scomi and its national oil company end users.
The company said the order and the framework agreement gave it confidence it could meet its 2014 market expectations and would see "subtantial increases in revenues from 2015."
Analyst Dr Mike Mitchell at Panmure Gordon said:
Investors have been waiting a long time but this morning their patience is rewarded with a major milestone for Graphene NanoChem, with the first purchase order for PlatDrill. The order, from Scomi Oiltools for use by an unnamed national oil company end-customer is part of the framework agreement, as announced on 26 November, and represents 7,800 barrels or around £1.0m at the top line. This, alongside future orders within the framework, further underpins our expectations for 2014.
While later of course than we'd originally expected, this is undoubtedly a positive step forward. We reiterate our buy recommendation, target price 150p.
www.theguardian.com/business/marketforceslive/2014/jul/02/graphene-nanochem-jumps-milestone-order
Graphene NanoChem gets PlatDril order
2 July 2014 | 07:59am
StockMarketWire.com - Graphene NanoChem has achieved a prominent milestone with the first purchase order for its graphene-enhanced PlatDrill series oilfield chemicals.
Highlights:
· Order from Scomi Oiltools Sdn Bhd for use by a National Oil Company end-customer
· Framework agreement entered into with Scomi Oiltools as announced on 26 November 2013
· Initial deployment and field introduction of 7,800 barrels (approximately 1000 metric tonnes) into a fully-planned four well onshore drilling programme commencing in July 2014
· Purchase Order represents beginning of commercial roll-out following two years of extensive testing by Scomi Oiltools and end-customers
· Purchase Order, together with visibility of future orders under framework agreement, gives management significant confidence of meeting the market's expectations for 2014
· The revenue from the initial purchase order is estimated to be £1.0 million and is payable on delivery
· The Group remains fully funded to carry out its existing pipeline
www.stockmarketwire.com/article/4841389/Graphene-NanoChem-gets-PlatDril-order.html#sthash.De66XW3u.dpuf
Graphene NanoChem gets PlatDril order
2 July 2014 | 07:59am
StockMarketWire.com - Graphene NanoChem has achieved a prominent milestone with the first purchase order for its graphene-enhanced PlatDrill series oilfield chemicals.
Highlights:
· Order from Scomi Oiltools Sdn Bhd for use by a National Oil Company end-customer
· Framework agreement entered into with Scomi Oiltools as announced on 26 November 2013
· Initial deployment and field introduction of 7,800 barrels (approximately 1000 metric tonnes) into a fully-planned four well onshore drilling programme commencing in July 2014
· Purchase Order represents beginning of commercial roll-out following two years of extensive testing by Scomi Oiltools and end-customers
· Purchase Order, together with visibility of future orders under framework agreement, gives management significant confidence of meeting the market's expectations for 2014
· The revenue from the initial purchase order is estimated to be £1.0 million and is payable on delivery
· The Group remains fully funded to carry out its existing pipeline
www.stockmarketwire.com/article/4841389/Graphene-NanoChem-gets-PlatDril-order.html#sthash.De66XW3u.dpuf
FORM 8-K
Executive Employment Agreement with Sterling Scott
Date: June 25, 2014
www.sec.gov/Archives/edgar/data/1161582/000107997414000515/growlife8k6212014.htm
Full Exercise of Underwriters' Option to Purchase Additional ADSs
www.investegate.co.uk/gw-pharmaceuticals--gwp-/rns/exercise-of-underwriters--option-to-purchase-adss/201406240918153668K/